Brand Name | Status | Last Update |
---|---|---|
2-oak mix, red/white pollen 3-oak mix, black/blackjack/post pollen 3-ragweed mix, giant/short/western pollen 4-pine mix, austrian/loblolly/scotch/w... | Biologic Licensing Application | 2011-03-11 |
ad incontinence support | C200263 | 2025-03-07 |
avance incontinence care | C200263 | 2024-05-11 |
bioelements, inc. | OTC monograph not final | 2012-01-17 |
ca-rezz - long term care - incontinent cleanser | C200263 | 2024-12-26 |
ca-rezz - norisc - incontinent wash | C200263 | 2024-12-27 |
center-al - acacia longifolia pollen center-al - acer negundo pollen center-al - acer saccharum pollen center-al - agrostis gigantea center-al - al... | Biologic Licensing Application | 2009-06-12 |
chain drug marketing association, inc. | C200263 | 2024-05-21 |
crooked creek distillery inc hand sanitizer | OTC monograph not final | 2020-03-25 |
cvs pharmacy,inc. | C200263 | 2024-08-16 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Acne vulgaris | D000152 | EFO_0003894 | L70 | — | — | 1 | — | — | 1 |
Psoriasis | D011565 | EFO_0000676 | L40 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Non-hodgkin lymphoma | D008228 | — | C85.9 | — | 1 | — | — | — | 1 |
Lymphoma | D008223 | — | C85.9 | — | 1 | — | — | — | 1 |
Follicular lymphoma | D008224 | — | C82 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Alzheimer disease | D000544 | EFO_0000249 | F03 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hepatocellular carcinoma | D006528 | — | C22.0 | — | — | — | — | 1 | 1 |
Hiv | D006678 | — | O98.7 | — | — | — | — | 1 | 1 |
Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | — | — | — | 1 | 1 |
Hepatitis c | D006526 | — | B19.2 | — | — | — | — | 1 | 1 |
Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | — | — | — | 1 | 1 |
Hepatitis b | D006509 | — | — | — | — | — | — | 1 | 1 |
Hepatitis | D006505 | — | K75.9 | — | — | — | — | 1 | 1 |
Hepatitis a | D006506 | EFO_0007305 | B15 | — | — | — | — | 1 | 1 |
Drug common name | Enoblituzumab |
INN | enoblituzumab |
Description | Enoblituzumab is a monoclonal antibody designed for the treatment of cancer. Formerly known as MGA271, the drug is a humanized IgG1κ monoclonal antibody recognizing human B7-H3, a member of the B7 family of immune regulators.
|
Classification | Antibody |
Drug class | monoclonal antibodies |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL3545373 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | M6030H73N9 (ChemIDplus, GSRS) |